Targeting IL-6 in the Treatment of Uveitic Macular Edema

16-week data from MEERKAT and SANDCAT on vamikibart

By: Rahul Khurana, MD, Michael A. Singer, MD

Retinal Physician January 16, 2026

Clinical Report: Targeting IL-6 in the Treatment of Uveitic Macular Edema

Overview

Vamikibart, an IL-6 inhibitor, shows promise in treating uveitic macular edema, with significant improvements in visual acuity and retinal anatomy observed in phase 3 trials. The treatment demonstrated a favorable safety profile compared to traditional steroid therapies.

Background

Uveitic macular edema is a leading cause of vision loss in patients with uveitis, affecting nearly 50% of patients despite systemic immunosuppression. Current treatments, primarily involving steroids, often lead to significant side effects, highlighting the need for alternative therapies. Targeting IL-6 presents a novel approach, as it is implicated in the pathophysiology of uveitis and macular edema.

Data Highlights

Trial	Dosage	Visual Acuity Improvement (letters)	Retinal Anatomy Change (µm)	Safety Profile
MEERKAT	0.25 mg / 1 mg	~10	~200	Low rates of intraocular inflammation, cataract, and intraocular pressure
SANDCAT	0.25 mg	~10	~200	Low rates of intraocular inflammation, cataract, and intraocular pressure

Key Findings

Vamikibart demonstrated a significant improvement in visual acuity, with patients gaining approximately 10 letters compared to 3-4 letters in the sham group.
Both doses of vamikibart (0.25 mg and 1 mg) reduced retinal thickness by about 200 µm.
Statistical significance was achieved for the primary endpoint in the MEERKAT trial for both doses, while the SANDCAT trial showed significance for the 0.25 mg dose only.
Vamikibart was well-tolerated with low rates of intraocular inflammation, cataract formation, and intraocular pressure elevation.
The pharmacokinetic data indicated that IL-6 suppression lasted up to 6 months post-injection.

Clinical Implications

The introduction of vamikibart as a treatment option for uveitic macular edema may reduce the reliance on steroids, thereby minimizing associated side effects. Its long-lasting effects could lead to less frequent injections, improving patient compliance and overall treatment experience.

Conclusion

Vamikibart represents a promising advancement in the management of uveitic macular edema, with its targeted approach to IL-6 inhibition potentially transforming treatment paradigms in this challenging condition.

PentaVision

Retinal Physician